Status:
COMPLETED
Long-term Follow-up of Fingolimod Phase II Study Patients
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Multiple Sclerosis, Relapsing Forms of Multiple Sclerosis
Eligibility:
All Genders
Phase:
PHASE4
Brief Summary
This study collected follow-up data on approximately 90% of participants who were randomized and received one dose of study drug in FTY720D2201 (D2201). No study drug was given or required. Participan...
Detailed Description
This was a multicenter follow-up study of patients originally enrolled in the Phase 2 D2201 study. Patients did not receive any protocol specified treatment. The original D2201 study sites who agreed ...
Eligibility Criteria
Inclusion
- Written informed consent must be obtained before any assessment is performed.
- Randomized in study FTY720D2201 and received at least one dose of study drug.
Exclusion
- None
Key Trial Info
Start Date :
June 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2015
Estimated Enrollment :
177 Patients enrolled
Trial Details
Trial ID
NCT02307838
Start Date
June 1 2014
End Date
December 1 2015
Last Update
March 23 2017
Active Locations (26)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Investigative Site
Ottawa, Ontario, Canada, K1H 8L6
2
Novartis Investigative Site
Toronto, Ontario, Canada, M5B 1N9
3
Novartis Investigative Site
Montreal, Quebec, Canada, H2L 4M1
4
Novartis Investigative Site
Montreal, Quebec, Canada, H3A 2B4